New opportunities for the development of cancer immunotherapies

Cancer Journal from Scientific American

Volumn 4, Issue SUPPL. 1, 1998, Pages

  Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER RESEARCH; DRUG RESEARCH; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; EPITOPES; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASMS; UNITED STATES;

EID: 0031866048     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Woglom WH. Immunity to transplantable tumors. Cancer Res 1929;4:129.
2. Morgan DA, Ruscetti FW, Gallo RG. Selective in vitro growth of T-lymphocytes from normal bone marrow. Science 1976;193: 1007-1008.
3. Rosenberg SA, Lotze MT, Muul TM et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485-1492.
4. Rosenberg SA, Yang JC, Topalian SL et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 1994;271:907-913.
5. Itoh K, Platcoucas DC, Balch CM. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas: activation by interleukin 2 and autologous tumor cells and involvement of theT cell receptor. J Exp Med 1988;168:1419-1441.
6. Topalian SL, Rosenberg SA. Tumor-specific lysis by long-term cultured tumor infiltrating lymphocytes. Surg Forum 1987;38: 434-435.
7. Crowley NJ, Darrow TL, Quinn-Allen MA et al. MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. J Immunol 1991;146:1692-1699.
8. O'Neil BH, Kawakami Y, Restifo NP et al. Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA. J Immunol 1993; 151:1410-1418.
9. Schwartzentruber DJ, Solomon D, Rosenberg SA et al. Characterization of lymphocytes infiltrating human breast cancer: specific immune reactivity detected by measuring cytokine secretion. J Immunother 1992;12:1-12.
10. Dadmartz R, Sgagias MK, Rosenberg SA et al. CD4+ T lymphocytes infiltrating human breast cancer recognize autologous tumor in an MHC-class-II restricted fashion. Cancer Immunol Immunother 1995;40:1-9.
11. van Pel A, van der Bruggen P, Coulie PG et al. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev 1995;145:229-250.
12. Rosenberg SA. The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens. Annu Rev Med 1996;47:481-491.
13. Cole DJ, Weil DP, Shilyansky J et al. Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen. Cancer Res 1995;55: 748-752.
14. Rivoltini L, Kawakami Y, Sakaguchi K et al. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995;154:2257-2265.
15. Jaeger E, Bernhaard H, Romero P et al. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int J Cancer 1996;66:162-169.
16. Salgaller ML, Marincola FM, Cormier JA et al. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 1996; 56:4749-4757.
17. Parkhurst MR, Salgaller ML, Southwood S et al. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0210 binding residues. J Immunol 1996;157:2539-2548.
18. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metatastic melanoma. Nat Med 1998; 4:321-327.